Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05614726 · ClinicalTrials.gov registry record · NA
A Probiotic Blend Reduces Gastrointestinal Symptoms and Positively Impacts Microbiota Modulation in a Randomized Study
A NA study of Constipation and Microbiota, sponsored by The Center for Applied Health Sciences.
- Completed
- Registry status
- NA
- Development phase
- 52
- Enrollment target
- 1
- Study location
NCT05614726 is a NA study of Constipation and Microbiota that has completed, run by The Center for Applied Health Sciences. The registered enrollment target is 52 participants, below the 204-participant average among 54 other Constipation trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05614726, a NA study of Constipation and Microbiota, has completed, sponsored by The Center for Applied Health Sciences.
- COMPLETED
- Registry status
- NA
- Development phase
- 52 participants
- Enrollment target
- 1
- Study location
Study Summary
This randomized, placebo-controlled, double-blind study will determine the effect of daily supplementation with a probiotic blend in 60 apparently healthy men and women recruited at a single investigational center in Northeast Ohio (i.e., The Center for Applied Health Sciences). Subjects will attend three study visits. During Visit 1, subjects will be screened for participation \[i.e., medical history, routine blood work, background baseline diet\]. During Visits 2 and 3 subjects will complete questionnaires that assess their gastrointestinal health (e.g., abdominal discomfort/bloating, constipation, regularity, stool consistency). Visits 2 and 3 will correspond to before (week 0) and after six weeks of supplementation, respectively, with the probiotic dietary supplement or placebo.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT 575mg [30 billion colony forming units] probiotic blend of Bifidobacterium breve, Lactobacillus acidophilus, Lacticaseibacillus rhamnosus, Saccharomyces boulardii, and alpha amylase
Study Locations (1)
Ohio
- The Center for Applied Health Sciences - Canfield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2021-06-18 |
| Est. Completion | 2022-03-17 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05614726
The ClinicalTrials.gov registry entry for NCT05614726 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 204-participant average among 54 other Constipation trials with a reported enrollment target (75% lower). The listed sponsor is The Center for Applied Health Sciences, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Constipation appearing as the primary indexed condition, and to 1 intervention - of which 575mg [30 billion colony forming units] probiotic blend of Bifidobacterium breve, Lactobacillus acidophilus, Lacticaseibacillus rhamnosus, Saccharomyces boulardii, and alpha amylase is the first listed.
NCT05614726 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT05614726 about?
NCT05614726 is a clinical study titled "A Probiotic Blend Reduces Gastrointestinal Symptoms and Positively Impacts Microbiota Modulation in a Randomized Study". This randomized, placebo-controlled, double-blind study will determine the effect of daily supplementation with a probiotic blend in 60 apparently healthy men and women recruited at a single investigational center in Northeast Ohio (i.e., The Center for Applied Health Sciences). Subjects will atten...
What is the current status of trial NCT05614726?
This trial is currently completed. It is a NA study. The enrollment target is 52 participants. The study started on 2021-06-18. Estimated completion is 2022-03-17.
What conditions does trial NCT05614726 study?
This clinical trial studies the following conditions: Constipation, Microbiota, Candida.
What interventions are being tested in trial NCT05614726?
The interventions under investigation include: 575mg [30 billion colony forming units] probiotic blend of Bifidobacterium breve, Lactobacillus acidophilus, Lacticaseibacillus rhamnosus, Saccharomyces boulardii, and alpha amylase (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT05614726?
This trial is sponsored by The Center for Applied Health Sciences, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05614726 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Constipation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Optimization of Postoperative Bowel Habits
RECRUITING · NA
-
Management of Dyssynergic Defecation
RECRUITING · NA
-
Interrogating the Pathophysiological Mechanisms of Constipation in Patients With Systemic Sclerosis
RECRUITING · NA
-
Fecobionics in Biofeedback Therapy in Dyssynergia Patients
RECRUITING · NA
-
Understanding Mechanisms of Normal and Disordered Defecation
RECRUITING · NA
-
Impact of Weizmannia (Bacillus) Coagulans JBI-YZ6.3 on Gut Health and Fecal Microbiome Changes
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.